AnaptysBio Files 8-K on Nov 26

Ticker: ANAB · Form: 8-K · Filed: Nov 26, 2025 · CIK: 1370053

Anaptysbio, Inc 8-K Filing Summary
FieldDetail
CompanyAnaptysbio, Inc (ANAB)
Form Type8-K
Filed DateNov 26, 2025
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, financials

Related Tickers: ANAB

TL;DR

ANAB filed an 8-K today, mostly boilerplate but check for Reg FD updates.

AI Summary

AnaptysBio, Inc. filed an 8-K on November 26, 2025, reporting on events that occurred on the same date. The filing primarily concerns Regulation FD disclosures and includes financial statements and exhibits. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This filing indicates AnaptysBio is making disclosures to the SEC, which could relate to ongoing business operations or regulatory compliance.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for disclosures and exhibits, with no immediate indication of significant negative events.

Key Players & Entities

  • ANAPTYSBIO, INC (company) — Registrant
  • November 26, 2025 (date) — Date of Report
  • Delaware (jurisdiction) — State of Incorporation
  • 10770 Wateridge Circle, Suite 210, San Diego, CA 92121 (address) — Principal Executive Offices
  • 858-362-6295 (phone_number) — Registrant's Telephone Number

FAQ

What specific Regulation FD disclosures are being made by AnaptysBio?

The provided excerpt does not detail the specific content of the Regulation FD disclosures, only that they are part of the 8-K filing.

Are there any new financial statements included in this 8-K filing?

The filing indicates that financial statements and exhibits are included, but the excerpt does not provide details or figures from these statements.

What is the primary purpose of this 8-K filing for AnaptysBio?

The primary purpose is to report on events occurring on November 26, 2025, including Regulation FD disclosures and the submission of financial statements and exhibits.

Has AnaptysBio changed its name or address recently?

The filing notes former company names (ANAPTYSBIO INC and ANAPTYS BIOSCIENCES INC) and their respective name change dates (20080828 and 20060724), but does not indicate a recent change.

What is AnaptysBio's fiscal year end?

AnaptysBio's fiscal year ends on December 31 (1231).

Filing Stats: 665 words · 3 min read · ~2 pages · Grade level 10.4 · Accepted 2025-11-26 16:00:38

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share ANAB The Nasdaq Stock Marke

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On November 20, 2025, as previously announced, AnaptysBio, Inc. (" AnaptysBio ") filed a Verified Complaint (the " AnaptysBio Complaint ") in Delaware Chancery Court, requesting a court declaration that TESARO, Inc. (" Tesaro ") has materially breached the parties' Collaboration and Exclusive License Agreement (" Collaboration Agreement ") and that GlaxoSmithKline (" GSK " ) , Tesaro's corporate parent, has tortiously interfered with the Collaboration Agreement. AnaptysBio has requested that the court declare that AnaptysBio is entitled to all rights and remedies under the Collaboration Agreement. On November 26, 2025, the AnaptysBio Complaint was publicly filed. A copy of the publicly filed version of the AnaptysBio Complaint is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The summary above is qualified in its entirety by reference to the full text of the AnaptysBio Complaint. Also on November 26, 2025, Tesaro and GSK publicly filed their complaint against AnaptysBio claiming that AnaptysBio has breached the Collaboration Agreement (captioned as Tesaro, Inc. and Tesaro Development, Ltd. v. AnaptysBio, Inc., C.A. No. 2025-1357-KSJM (Del. Ch.)). The information in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Title or Description 99.1 Complaint filed by AnaptysBio, Inc. against TESARO, Inc. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. AnaptysBio, Inc. Date: November 26, 2025 By: /s/ Eric Loumeau Name: Eric Loumeau Title: Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.